Navigation Links
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Date:2/26/2010

"The last 6 months have been very challenging for the entire Gaucher community, and the approval of VPRIV brings an important new treatment option to patients suffering from Type 1 Gaucher disease," said Rhonda Buyers, CEO / Executive Director, National Gaucher Foundation (NGF). "We at the NGF are excited about this approval, and by the steps that Shire has taken to improve access to treatments for patients with life-altering conditions. This co-pay program will greatly assist the Gaucher patient population, and we appreciate the fact that Shire has taken the time to listen to us and to act on the needs of patients."

More about VPRIV

The VPRIV application has also been granted accelerated assessment by the European Medicines Agency (EMA) in the European Union (EU). Shire expects to launch VPRIV in the EU by the end of 2010 and in other countries beginning in 2011.

Full prescribing information for VPRIV can be found at http://www.VPRIV.com. For information on Shire's OnePathSM services visit

SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... and BRUSSELS, Belgium (PRWEB) June 03, 2015 ... beyond, photonics plays an important part in enabling success ... European Commission. Innovation and technology leaders helped bring focus ... thematic sessions during the Photonics21 annual meeting ... a sponsor of the event, held 28 and 29 ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has ... by Product , Test, Application & End User - ... The bioburden testing market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... limit testing market is segmented into consumables and instruments. ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced ... Application & by Products - Global Forecast to 2020" ... genotyping market is expected to reach $17.0 Billion in ... of 22.3% during the forecast period of 2015 to ... the availability of a range of products for wide ...
(Date:6/2/2015)... , June 2, 2015   BioClinica ® , ... provider, today announced that David Peters , an ... Executive Vice President and Chief Financial Officer (CFO) and ... Peters brings more than 25 years of financial ... "David has extensive and deep knowledge in all areas ...
Breaking Biology Technology:Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2
... BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), ... that at ATS Labs, using a Quantitative Disk ... (C.diff) spores, BioNeutral,s Ygiene(TM) Hospital Grade antimicrobial delivered ... Clostridium Difficile, an extremely dangerous and difficult to ...
... Novavax, Inc. (Nasdaq: NVAX ) ... their joint venture in India under the agreement signed ... joint venture, called CPL Biologicals Pvt. Ltd., will develop ... using technology contributed from Novavax and Cadila Pharmaceuticals. ...
... safety of their drinking water for granted, that ordinary tap ... of Tel Aviv University,s School of Physics and Astronomy. ... natural disaster or sabotage, the physicist has developed a new ... water supply in real time. Modifying special fibers ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase 2BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase 3Cadila Pharmaceuticals Launches Joint Venture With Novavax in India 2Cadila Pharmaceuticals Launches Joint Venture With Novavax in India 3Cadila Pharmaceuticals Launches Joint Venture With Novavax in India 4Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/25/2015)... -- Australia,s market for wearable technologies is considered to be ... of several trials and prototypes. The release of the ... ignite interest in wearables as well as accelerate sales ... This in turn will spur greater innovation from other ... vendors and distributors. Photo - ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... reserves such as gold, diamond and natural gas isn,t ... look. Now researchers at Tel Aviv University have modernized the ... signs of lucrative resources that could lurk beneath our feet. ... first time, Prof. Lev Eppelbaum of TAU,s Department of ...
... Bethesda, MDA new research report published in The ... and scientists better understand a rare genetic disease that ... decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome. ... genes responsible for the healthy renewal of rods and ...
... had officials along the East Coast preparing for mass ... the University of Delaware were grabbing their best data ... It was a rare opportunity for the scientists ... as Irene threatened to be the biggest hurricane to ...
Cached Biology News:The geophysicist's guide to striking it rich 2Scientists unravel the cause of rare genetic disease: Goldman-Favre Syndrome explained 2Hurricane Irene: Scientists collect water quality and climate change data from huge storm 2
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Vector NTI allows you to store and ... data in a secure central relational database. ... creates an invaluable resource for clone tracking ... easily for immediate analysis. LabShare software integrates ...
... Protein A and Protein G bind ... immunoglobulins. Protein A and Protein G conjugates ... purify immunoglobulins (antibodies) and immunoglobulin subtypes from ... and other biological fluids. These reagents are ...
Biology Products: